53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

Diabetic Health Maintenance Protocol Overview

Chronic hyperglycemia exerts devastating pathophysiological damage across both the microvasculature (retinal capillaries, renal glomeruli, endoneurial microvessels) and macrovasculature (coronary arteries, cerebral circulation, peripheral arterial beds). Family physicians serve as the primary coordinators of systematic, longitudinal surveillance designed to identify early subclinical organ injury and deploy guideline-directed disease-modifying therapies.

                  ANNUAL COMPREHENSIVE DIABETIC HEALTH MAINTENANCE SCHEDULE

   Surveillance Domain           Screening Modality & Frequency               Diagnostic Target / Thresholds
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Glycemic Control              HbA1c every 3 months (if uncontrolled)       • Individualized target (<7.0% general;
                                 or every 6 months (if stable at target)        <6.5% young; <8.0-8.5% frail/elderly)

   Diabetic Nephropathy          Annual Spot Urine Albumin-to-Creatinine      • Normal: UACR < 30 mg/g
                                 Ratio (UACR) + Serum Creatinine / eGFR        • Microalbuminuria: UACR 30 to 299 mg/g
                                                                              • Macroalbuminuria: UACR >= 300 mg/g

   Diabetic Retinopathy          Dilated eye exam by ophthalmologist/         • T2D: Start at diagnosis; annually
                                 optometrist (every 1-2 years if normal)      • T1D: Start within 5 yr of diagnosis

   Diabetic Neuropathy &         Annual Comprehensive Diabetic Foot Exam:     • Loss of Protective Sensation (LOPS):
   Foot Complications            • 10-g Semmes-Weinstein monofilament           failure to feel >= 1 of 10 sites
                                 • 128-Hz vibration, pinprick, Achilles reflex • ABI < 0.90 confirms PAD
                                 • Visual skin/deformity exam, pedal pulses    • Charcot detection (erythema/warmth)

   Blood Pressure Surveillance   Screened at every clinical visit             • Target: < 130/80 mmHg for all adults

   Lipid Panel                   Annual fasting or non-fasting lipid profile  • Statin: Moderate-to-high intensity
                                                                              • Target LDL-C: < 70 or < 55 mg/dL

   Dental & Periodontal Exam     Annual professional dental evaluation        • Periodontitis exacerbates dysglycemia
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

---

Microvascular Complication 1: Diabetic Nephropathy Surveillance & Intervention

Diabetic Kidney Disease (DKD) develops in 30% to 40% of patients with diabetes and represents the single leading cause of end-stage renal disease (ESRD) requiring chronic maintenance hemodialysis or renal transplantation in the United States.

Pathophysiological Natural History

1. Glomerular Hyperfiltration & Hypertrophy: Early hyperglycemia induces renal vasodilatation, predominantly driven by efferent arteriolar constriction (angiotensin II-mediated) and afferent arteriolar relaxation (SGLT2-mediated glucose/sodium hyper-reabsorption blunting tubuloglomerular feedback). This generates intense intraglomerular capillary hypertension.
2. Mesangial Expansion & Matrix Accumulation: Hyperglycemia induces advanced glycation end-products (AGEs) and transforming growth factor-beta (TGF-beta), stimulating mesangial cell proliferation and dense extracellular matrix deposition.
3. Basement Membrane Thickening & Podocyte Loss: Podocyte detachment and glomerular basement membrane thickening disrupt the filtration slit diaphragm, permitting albumin leakage.
4. Nodular Glomerulosclerosis (Kimmelstiel-Wilson Lesions): Pathognomonic acellular, PAS-positive, eosinophilic nodular lesions form within glomerular mesangial areas, leading to progressive capillary obliteration, nephrotic-range proteinuria, and declining GFR.

Screening Protocol & Staging

Screening requires an annual random spot Urine Albumin-to-Creatinine Ratio (UACR) obtained from an early-morning first-void urine specimen, coupled with serum creatinine and estimated GFR (eGFR):

                  ALBUMINURIA STAGING & THE CONFIRMATION RULE

   Stage Category          UACR (mg/g)       UACR (mg/mmol)    Clinical Classification & Confirmation Rule
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════
   Stage A1 (Normal)       < 30 mg/g         < 3 mg/mmol       Normal to mildly increased albumin excretion.

   Stage A2 (Micro)        30 to 299 mg/g    3 to 30 mg/mmol   Moderately increased albuminuria (Microalbuminuria).
                                                               Earliest clinical indicator of nephropathy.

   Stage A3 (Macro)        >= 300 mg/g       > 30 mg/mmol      Severely increased albuminuria (Macroalbuminuria).
                                                               High risk of rapid eGFR loss and ESRD.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════

[!IMPORTANT] THE TWO-OUT-OF-THREE CONFIRMATION RULE Urinary albumin excretion fluctuates markedly in response to physiological stressors. Transient, false-positive elevations in UACR occur with strenuous exercise within 24 hours, acute febrile illness, urinary tract infection, marked systemic hypertension, acute decompensated heart failure, severe acute hyperglycemia, and gross hematuria. Therefore, a diagnosis of persistent albuminuria requires documenting abnormal UACR on at least 2 of 3 specimens collected over a 3 to 6-month period.

Evidence-Based Cardiorenal Pharmacotherapeutic Interventions

• Renin-Angiotensin System (RAS) Inhibition:
  • An ACE inhibitor (e.g., lisinopril, enalapril) or Angiotensin Receptor Blocker (ARB) (e.g., losartan, valsartan) is the mandatory first-line agent for patients with diabetes who have hypertension AND persistent albuminuria (UACR >=30 mg/g).
  • Mechanism: Selectively dilates the efferent arteriole, reducing intraglomerular hydrostatic pressure and decreasing albumin filtration independent of systemic blood pressure reduction.
  • Titration & Monitoring: Titrate to the maximum approved, tolerated dose. Serum creatinine and potassium must be evaluated within 1 to 2 weeks after initiating or titrating therapy.
  • The 30% Creatinine Rule: An increase in serum creatinine of up to 30% from baseline reflects hemodynamic intraglomerular pressure reduction; it is expected, renoprotective, and does NOT warrant drug cessation unless progressive azotemia or uncontrollable hyperkalemia occurs.
  • Critical Board Trap: ACE inhibitors and ARBs are NOT recommended for primary prevention of diabetic kidney disease in diabetic patients who have normal blood pressure and normal albumin excretion (UACR <30 mg/g). Furthermore, never combine an ACE inhibitor with an ARB; dual RAS blockade increases the risk of acute kidney injury, severe hyperkalemia, and syncope without conferring additional renal protection (ONTARGET trial).
• SGLT2 Inhibitors:
  • Recommended for all patients with type 2 diabetes, CKD, and eGFR >=20 mL/min/1.73m2 with UACR >=200 mg/g (or eGFR 20-60 mL/min/1.73m2). Proven in CREDENCE, DAPA-CKD, and EMPA-KIDNEY to reduce the composite risk of sustained eGFR doubling, ESRD, and renal death by 30% to 40%.
• Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone):
  • Finerenone selectively blocks overactivated mineralocorticoid receptors, suppressing downstream proinflammatory and profibrotic pathways in the kidney and heart.
  • Proven in the FIDELIO-DKD and FIGARO-DKD trials to significantly reduce CKD progression and cardiovascular events in patients with type 2 diabetes with eGFR >=25 mL/min/1.73m2, normal serum potassium (<=4.8 mEq/L), and persistent albuminuria (UACR >=30 mg/g) despite maximally tolerated ACEi/ARB therapy.

---

Microvascular Complication 2: Diabetic Retinopathy Screening & Staging

Diabetic retinopathy is a highly specific neurovascular complication and remains the leading cause of new-onset legal blindness among working-age adults (aged 20 to 74 years).

Screening Schedule Guidelines

• Type 2 Diabetes: Comprehensive dilated eye examination by an ophthalmologist or optometrist at the time of initial diabetes diagnosis, because up to 20% of patients already have retinopathy due to years of unrecognized asymptomatic hyperglycemia. If the initial exam is normal and glycemia is well controlled, exams may be performed every 1 to 2 years; if retinopathy is present, exams must occur at least annually.
• Type 1 Diabetes: Initial dilated eye examination within 5 years after diabetes diagnosis (prepubertal disease duration rarely produces vision-threatening retinopathy), followed by annual examinations.
• Pregnancy Considerations: Women with pre-existing type 1 or type 2 diabetes who are planning pregnancy or who become pregnant must receive a comprehensive eye exam in the first trimester and be monitored closely throughout pregnancy and for 1 year postpartum due to the risk of rapid retinopathy progression. (This requirement does not apply to gestational diabetes).

                  SPECTRUM OF DIABETIC RETINOPATHY & MANAGEMENT

   Classification      Pathognomonic Funduscopic Findings           Pathophysiology & Management Strategy
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Mild NPDR           Microaneurysms alone                         • Capillary outpouchings from pericyte loss.
                                                                    • Surveillance: Annual dilated exam.

   Moderate NPDR       Microaneurysms, 'dot-and-blot' hemorrhages,  • Vascular leakage & capillary occlusion.
                       hard exudates, cotton-wool spots             • Hard exudates = lipid deposits.
                                                                    • Cotton-wool spots = retinal nerve infarcts.

   Severe NPDR         The '4-2-1 Rule':                            • High risk (> 50%) of progression to
                       • Severe intraretinal hemorrhages in ALL 4     proliferative disease within 1 year.
                         quadrants, OR                              • Close surveillance q3-4 months;
                       • Venous beading in >= 2 quadrants, OR         consider early anti-VEGF or PRP.
                       • Prominent IRMA in >= 1 quadrant

   Proliferative       NEOVASCULARIZATION of the disc (NVD) or      • Retinal ischemia triggers massive VEGF.
   Retinopathy (PDR)   retina (NVE), preretinal/vitreous hemorrhage, • Fragile new vessels bleed easily.
                       fibrovascular proliferation, traction        • Urgent Treatment: Panretinal Photocoagulation
                       retinal detachment                             (PRP) laser or Intravitreal Anti-VEGF.

   Diabetic Macular    Retinal thickening and hard exudate          • Occurs at ANY stage of NPDR or PDR!
   Edema (DME)         accumulation involving or threatening        • LEADING CAUSE OF LEGAL BLINDNESS.
                       the fovea centralis                          • First-Line: Intravitreal Anti-VEGF injections
                                                                      (Aflibercept, Ranibizumab, Faricimab).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Advanced Complications of Proliferative Disease

• Vitreous Hemorrhage: Fragile neovascular vessels rupture into the vitreous humor. Patients present with sudden, painless onset of floaters, dark cobwebs, or complete visual blackouts.
• Traction Retinal Detachment: Fibrovascular membranes contract, mechanically pulling the neurosensory retina away from the underlying retinal pigment epithelium. Presents with visual field defects ('curtain descending') without flashes/floaters; requires surgical pars plana vitrectomy.
• Neovascular Glaucoma: Neovascularization invades the anterior chamber iris and iridocorneal filtration angle, occluding trabecular meshwork outflow, causing intractable intraocular pressure elevation and acute ocular pain.

---

Microvascular Complication 3: Diabetic Neuropathy & Comprehensive Foot Exam

Diabetic peripheral neuropathy encompasses a diverse spectrum of sensory, motor, and autonomic nerve fiber injury driven by sorbitol accumulation, oxidative stress, and microvascular endoneurial ischemia.

Clinical Phenotypes of Diabetic Neuropathy

1. Distal Symmetric Polyneuropathy (DSPN): The classic 'stocking-glove' sensory neuropathy (>80% of neuropathies). Small unmyelinated C-fibers and thinly myelinated A-delta fibers are damaged first (burning pain, electrical shocks, allodynia, thermal sensory loss), followed by large myelinated A-beta fibers (loss of vibration, light touch, proprioception, diminished Achilles reflexes, sensory ataxia).
2. Diabetic Autonomic Neuropathy (DAN):
   • Cardiovascular: Resting tachycardia (>100 bpm), fixed non-variable heart rate, orthostatic hypotension (fall in systolic BP >=20 mmHg or diastolic BP >=10 mmHg within 3 minutes of standing without compensatory heart rate acceleration), and 'silent' painless myocardial infarction.
   • Gastrointestinal: Diabetic gastroparesis (early satiety, postprandial fullness, nausea, vomiting of undigested food hours after ingestion; confirmed by 4-hour gastric emptying scintigraphy showing >10% retention; treat with small frequent meals, metoclopramide short-term, or erythromycin) and nocturnal diabetic diarrhea.
   • Genitourinary: Neurogenic bladder (detrusor hyporeflexia, urinary retention, overflow incontinence), erectile dysfunction, retrograde ejaculation.
   • Sudomotor: Distal anhidrosis (dry, cracked, fissured feet predisposing to skin breakdown) and gustatory facial sweating.
   • Hypoglycemic Unawareness: Blunting of sympathoadrenal warning signs (palpitations, tremor, anxiety), allowing patients to plunge directly into neuroglycopenic coma.

The Annual Comprehensive Diabetic Foot Examination Protocol

Every adult with diabetes must undergo a comprehensive foot evaluation at least annually to detect risk factors for ulceration and lower-extremity amputation:

                  COMPREHENSIVE DIABETIC FOOT EXAMINATION PROTOCOL

   Exam Component           Clinical Maneuver & Technique                  Abnormal Finding & Significance
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Visual Inspection        Inspect dorsal, plantar, and interdigital skin; • Calluses: pre-ulcerative hyperkeratosis.
                            assess structural architecture.                • Maceration, tinea pedis, onychomycosis.
                                                                           • Deformities: bunions, hammer/claw toes.

   10-g Semmes-Weinstein    Apply monofilament perpendicular to skin       • Inability to perceive monofilament at
   Monofilament Testing     until it buckles; hold for 1 to 2 seconds.       >= 1 of 10 sites confirms LOSS OF
   (The Gold Standard!)     Test 10 plantar sites: plantar hallux, 1st,      PROTECTIVE SENSATION (LOPS).
                            3rd, 5th metatarsal heads, midfoot, heel.      • Single greatest risk for foot ulceration!

   Vibration Perception     Apply vibrating 128-Hz tuning fork to the bony  • Premature loss of vibration perception
                            prominence of the dorsal distal hallux.          precedes monofilament loss (large fibers).

   Pinprick & Reflexes      Disposable pin to dorsal hallux; Achilles tap.  • Tests small pain fibers & S1 reflex arc.

   Vascular Assessment      Palpate dorsalis pedis & posterior tibial      • Absent pulses or claudication prompts
                            arteries; evaluate capillary refill & hair loss. Ankle-Brachial Index (ABI) testing.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

• Ankle-Brachial Index (ABI) Interpretation in Diabetes:
  • Normal: 0.90 to 1.30.
  • Peripheral Artery Disease (PAD): ABI < 0.90.
  • Mönckeberg Medial Calcinosis Trap: An ABI >1.30 or >1.40 indicates non-compressible, heavily calcified medial arterial walls common in diabetes; it does NOT mean normal circulation! In this setting, clinicians must measure the Toe-Brachial Index (TBI), as digital arteries rarely calcify (normal TBI >=0.70; <0.70 confirms PAD).

Diabetic Peripheral Neuropathic Pain Pharmacotherapy

• First-Line FDA-Approved Agents:
  • Duloxetine: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) dosed at 60 mg orally once daily. Particularly beneficial if comorbid depression or anxiety.
  • Pregabalin: Alpha-2-delta calcium channel subunit ligand dosed at 75 to 150 mg twice daily (titrated to 300 mg/day). Adverse effects: sedation, dizziness, peripheral edema.
• Alternative Agents:
  • Gabapentin: Dosed from 300 mg up to 1800-3600 mg/day divided three times daily (requires renal adjustment for eGFR).
  • Tricyclic Antidepressants (TCAs: Amitriptyline, Nortriptyline): 25 to 75 mg at bedtime. Highly effective but carry significant anticholinergic side effects, orthostatic hypotension, and QT prolongation; caution in elderly patients.
  • Topical Capsaicin 8% Patch or topical lidocaine 5% patches.
  • Opioid Analgesics: Tramadol and opioid narcotics are strongly discouraged by the ADA and AAN due to substantial risks of dependence, tolerance, addiction, and lack of long-term durability.

Acute Charcot Neuroarthropathy (Neuropathic Osteoarthropathy)

Charcot neuroarthropathy is a devastating, limb-threatening complication characterized by progressive joint subluxation, periarticular fractures, and architectural collapse of the foot.

• Pathophysiology: Loss of protective sensation + autonomic-mediated arteriovenous shunting (producing bone hyperemia and demineralization) + repetitive unperceived mechanical trauma -> uncontrolled localized inflammatory response with dramatic upregulation of RANK-ligand (RANKL) and proinflammatory cytokines -> unchecked osteoclastic bone resorption, ligamentous laxity, microfractures, joint dislocation, and midfoot collapse.
• Clinical Presentation: Acute, unilateral, red, hot, swollen foot and ankle in a patient with profound sensory neuropathy. Pain is often surprisingly mild or absent due to nerve damage.
• The Critical Differential: Acute Charcot is frequently misdiagnosed as cellulitis, acute gout, or osteomyelitis:
  • Cellulitis vs. Charcot Differentiation Maneuver: In Charcot, the skin is completely intact without open ulcers or puncture wounds. Elevating the affected leg above the heart for 5 to 10 minutes causes rapid dissipation of erythema and edema due to venous draining of hyperemic blood. In bacterial cellulitis, erythema and induration persist despite elevation.
  • Infrared Dermal Thermometry: Skin temperature of the affected foot is >2.0°C (3.6°F) warmer than the contralateral unaffected foot.
• Chronic Deformity: Midfoot arch collapse produces the classic 'rocker-bottom foot' deformity with severe plantar bony prominences, leading to chronic intractable plantar ulcers, osteomyelitis, and secondary amputation.
• Immediate Management: Strict non-weight-bearing immobilization with Total Contact Casting (TCC) or a customized rigid pneumatic walker until active inflammation has resolved (monitored by infrared skin temperature normalization over 3 to 6 months).

---

Macrovascular Risk Reduction & Adult Diabetes Immunizations

Cardiovascular disease (coronary artery disease, ischemic stroke, peripheral arterial disease) accounts for >70% of all mortalities in type 2 diabetes. Glycemic control alone exerts only a modest impact on macrovascular outcomes; aggressive multi-factorial risk reduction is mandatory.

                  CARDIOVASCULAR RISK REDUCTION TARGETS & PROTOCOLS

   Clinical Domain        Guideline-Directed Recommendation               Target Goal / Agent Selection
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Blood Pressure         Target < 130/80 mmHg for all diabetic adults    • If UACR >= 30 mg/g: ACEi or ARB first-line
                          with hypertension. Screen at every visit.      • If UACR < 30 mg/g: ACEi, ARB, CCB, or thiazide

   Statin Therapy:        Ages 40 to 75 years without established ASCVD:  • Target: >= 30-49% LDL-C reduction
   Primary Prevention     MODERATE-INTENSITY STATIN                      • Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg
                          If multiple ASCVD risk factors or 10-yr risk    • If high risk: HIGH-INTENSITY STATIN
                          >= 20%: HIGH-INTENSITY STATIN                  (Atorvastatin 40-80 mg, Rosuva 20-40 mg)
                                                                         Target LDL-C < 70 mg/dL

   Statin Therapy:        All ages with ESTABLISHED ASCVD:                • HIGH-INTENSITY STATIN
   Secondary Prevention   HIGH-INTENSITY STATIN                           • Target LDL-C < 55 mg/dL
                                                                          • If LDL-C >= 55 mg/dL: Add Ezetimibe 10 mg;
                                                                            if still >= 55 mg/dL: Add PCSK9 inhibitor

   Antiplatelet Therapy:  All diabetic patients with established ASCVD:   • ASPIRIN 81 mg daily indefinitely
   Secondary Prevention   Secondary prevention against recurrent events   • Clopidogrel 75 mg daily if aspirin-allergic

   Antiplatelet Therapy:  Selected high-risk individuals after shared     • Routine aspirin for primary prevention is
   Primary Prevention     decision-making; not routinely recommended       NO LONGER recommended due to major bleeding!
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Comprehensive Adult Immunization Schedule for Diabetes

Because diabetes induces impaired neutrophil chemotaxis, blunted phagocytosis, and defective cell-mediated immunity, patients are vulnerable to severe vaccine-preventable infections:

                  MANDATED ADULT DIABETIC IMMUNIZATION SCHEDULE

   Vaccine Target                 Recommended Schedule & Formulations
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Influenza                      Annual quadrivalent inactivated (IIV4) or recombinant (RIV4) vaccine.

   Pneumococcal Disease           Ages 19 through 64 years with diabetes:
                                  • Single dose of PCV20 (Prevnar 20) alone, OR
                                  • PCV15 (Vaxneuvance) followed by PPSV23 (Pneumovax 23) >= 1 year later.
                                  • If PPSV23 received previously: give PCV20 or PCV15 >= 1 year after PPSV23.

   Hepatitis B                    2-dose (Heplisav-B at 0, 1 mo) or 3-dose (Engerix-B at 0, 1, 6 mo) series
                                  for ALL unvaccinated adults with diabetes aged 19 through 59 years
                                  (due to transmission risk via fingerstick glucometers); aged >=60 per discretion.

   Respiratory Syncytial Virus    Single dose of RSV vaccine (Arexvy or Abrysvo) for adults aged >=60 years
   (RSV)                          with chronic metabolic disorders including diabetes mellitus.

   COVID-19                       Annual updated seasonal COVID-19 vaccine formulation.

   Tetanus, Diphtheria,           One dose of Tdap if not received previously, followed by Td or Tdap booster
   Pertussis (Tdap/Td)            every 10 years.

   Herpes Zoster                  2-dose series of Recombinant Zoster Vaccine (Shingrix) at months 0 and 2-6
                                  for all adults aged >=50 years (and immunocompromised adults >=19 years).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════